Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

Two months af­ter an­nounc­ing Clay Sie­gall’s ar­rival in the C-suite, Mor­phim­mune has nabbed more funds to take its tar­get­ed can­cer ther­a­py bet to­ward the clin­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER